All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Recombinant Moloney murine leukemia virus (MMLV) retroviral vectors serve as efficient viral vector tools for introducing genes permanently into a wide variety of dividing cells, and provide an alternative to modify primary T cells. Creative biolabs has developed retroviral CAR vector pMMLV CD117 (CK6) h(BBζ), which is constructed for the engineering of T cells to target human CD117. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-CD117 antibody linked to CD137 (4-1BB) and CD3-zeta signaling domains. And the vector product was designed for the treatment of Gastrointestinal stromal tumors, Mast cell disease, Acute myelogenous lukemia, Piebaldism.
CAR Construction : Fig.1 CK6 binding to immobilized human c-Kit protein (EC50 = 0.06 nM) in ELISA. One representative experiment is shown with EC50. Lebron, M. B., Brennan, L., Damoci, C. B., Prewett, M. C., O’Mahony, M., Duignan, I. J., ... & Kotanides, H. (2014). A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer biology & therapy, 15(9), 1208-1218. |
CAR Construction : Fig 2. Flow cytometry staining analysis of CK6 binding to c-Kit receptor expressing SCLC tumor cell lines. Histograms indicate fluorescence signal of unstained cells (solid gray fill) and cells stained with either CK6 (black solid line) or human IgG (black dashed line). Lebron, M. B., Brennan, L., Damoci, C. B., Prewett, M. C., O’Mahony, M., Duignan, I. J., ... & Kotanides, H. (2014). A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer biology & therapy, 15(9), 1208-1218. |
CAR Construction : Fig 3. Flow cytometry staining analysis of CK7 binding to c-Kit receptor expressing melanoma tumor cell lines. Histograms indicate fluorescence signal of unstained cells (solid gray fill) and cells stained with either CK6 (black solid line) or human IgG (black dashed line). Lebron, M. B., Brennan, L., Damoci, C. B., Prewett, M. C., O’Mahony, M., Duignan, I. J., ... & Kotanides, H. (2014). A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer biology & therapy, 15(9), 1208-1218. |
CAR Construction : Fig 4. Flow cytometry staining analysis of CK8 binding to c-Kit receptor expressing leukemia cell lines. Histograms indicate fluorescence signal of unstained cells (solid gray fill) and cells stained with either CK6 (black solid line) or human IgG (black dashed line). Lebron, M. B., Brennan, L., Damoci, C. B., Prewett, M. C., O’Mahony, M., Duignan, I. J., ... & Kotanides, H. (2014). A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer biology & therapy, 15(9), 1208-1218. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD117 (CK6) h(41BB-CD3ζ) CAR, pMMLV (CAR-MV-01LX453). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION